MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12339-12344

  Feng, Shujun ^a   Pan, Wenjing ^a   Jin, Ye ^a   Zheng, Jianhua ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Invasion; Migration; MiR 25; Ovarian cancer; Proliferation

Indexed keywords

MICRORNA; MICRORNA 25; UNCLASSIFIED DRUG; LATS2 PROTEIN, HUMAN; MIRN25 MICRORNA, HUMAN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; LARGE TUMOR SUPPRESSOR 2 GENE; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; BINDING SITE; CELL MOTION; CHEMISTRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; NUCLEOTIDE SEQUENCE; OVARY TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84925283080     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2546-0     Document Type: Article

References (26)

1. Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20:72–6.
2. Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol. 2013;24:66–82.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
4. Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, et al. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977.
5. Kentwell J, Gundara JS, Sidhu SB: Noncoding RNAs in endocrine malignancy. The oncologist 2014
6. Alsaleh G, Gottenberg JE. Characterization of microRNAs and their targets. Methods Mol Biol. 2014;1142:55–63.
7. Li W, Liu Z, Chen L, Zhou L, Yao Y: MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. FEBS letters. 2014;588(9):1608–15.
8. Xia J, Guo X, Yan J, Deng K: The role of mir-148a in gastric cancer. Journal of cancer research and clinical oncology. J Cancer Res Clin Oncol. 2014;140(9):1451–56.
9. Li S, Li Y, Wen Z, Kong F, Guan X, Liu W. microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor alphapositive ovarian cancer cells. Mol Med Rep. 2014;9:1703–8.
10. Shen W, Song M, Liu J, Qiu G, Li T, Hu Y, et al. Mir-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One. 2014;9:e86871.
11. Wang X, Meng X, Li H, Liu W, Shen S, Gao Z: MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Translational Oncol: Off Publ Federat Spanish Oncol Soc Natl Cancer Institute Mexico. Biochem Biophys Res Commun. doi:10.1007/s12094-014-1178-6.
12. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the mir-200 family. Nat Commun. 2013;4:2427.
13. Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 2013;30:681.
14. Xu FX, Su YL, Zhang H, Kong JY, Yu H, Qian BY. Prognostic implications for high expression of mir-25 in lung adenocarcinomas of female non-smokers. Asian Pacific J Cancer Prev: APJCP. 2014;15:1197–203.
15. Zhao H, Wang Y, Yang L, Jiang R, Li W. Mir-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2014;385:207–13.
16. Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421:640–5.
17. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. Mir-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594–8.
18. Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the drosophila tumor suppressor gene lats/warts. Genomics. 2000;63:263–70.
19. Yu T, Bachman J, Lai ZC. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics. 2013;195:1193–6.
20. Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci U S A. 2013;110:17368–73.
21. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, et al. Phosphorylation of angiomotin by LATS1/2 kinases inhibits f-actin binding, cell migration, and angiogenesis. J Biol Chem. 2013;288:34041–51.
22. Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle. 2010;9:3892–903.
23. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:1380–5.
24. Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, et al. Mir-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 2012;11:4352–65.
25. Yang X, Yu J, Yin J, Xiang Q, Tang H, Lei X. Mir-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Die Pharmazie. 2012;67:645–51.
26. Xia Y, Gao Y: MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014;447(3):446--51.